Evofem Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(8,860) | $52,979 |
| Adjustments to reconcile net income (loss) to net cash, cash equivalents and restricted cash used in operating activities: | ||
| Loss on issuance of financial instruments | 3,300 | 6,776 |
| Gain on debt extinguishment | (977) | (75,337) |
| Change in fair value of financial instruments | (3,698) | (4,879) |
| Inventory write-down for excess & obsolescence | 63 | 1,576 |
| Loss on contingent liability | 840 | - |
| Stock-based compensation | 847 | 1,189 |
| Depreciation | 30 | 477 |
| Amortization of intangible asset | 619 | - |
| Noncash interest expense | 2,243 | 2,270 |
| Noncash right-of-use asset amortization | 107 | 1,304 |
| Net gain on lease termination | - | (466) |
| Net loss on disposal or impairment of property and equipment | 734 | 2,511 |
| Gain on accounts payable settlements | - | (2,096) |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (4,094) | (4,612) |
| Inventories | 57 | 2,106 |
| Prepaid and other assets | (265) | 3,661 |
| Accounts payable | (910) | 4,090 |
| Accrued expenses and other liabilities | 5,300 | 527 |
| Accrued compensation | 885 | 434 |
| Operating lease liabilities | (106) | (1,478) |
| Net cash and restricted cash used in operating activities | (3,885) | (8,968) |
| Cash flows from investing activities: | ||
| Payments related to asset acquisition | (555) | - |
| Purchases of property and equipment | (14) | (4) |
| Net cash and restricted cash used in investing activities | (569) | (4) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock - exercise of warrants | - | 290 |
| Borrowings under short term debt | 397 | 5,640 |
| Proceeds from issuance of Series F-1 Shares to Aditxt, including reinstatement proceeds - Related Party | 5,000 | - |
| Payments under short term debt and Notes – carried at fair value | (782) | (1,154) |
| Net cash and restricted cash provided by financing activities | 4,615 | 4,776 |
| Net change in cash, cash equivalents and restricted cash | 161 | (4,196) |
| Cash, cash equivalents and restricted cash, beginning of period | 580 | 4,776 |
| Cash, cash equivalents and restricted cash, end of period | $741 | $580 |
| Supplemental cash flow information: | ||
| Cash paid for interest | 159 | 338 |
| Cash paid for taxes | 8 | 4 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Exchange of convertible notes to Series E-1 Shares | - | 1,800 |
| Exchange of warrants and partial purchase rights value to Series F-1 Shares | - | 2,761 |
| Issuance of common stock upon exercise of purchase rights | 169 | 426 |
| Series E-1 Shares deemed dividends | 105 | 74 |
| Right-of-use assets obtained for lease liabilities (fleet lease renewals) | 90 | - |
| Issuance of common stock upon conversion of notes | 52 | - |
| Issuance of common stock upon exercise of warrants | 15 | - |
| Purchases of property and equipment included in accounts payable and accrued expenses | 84 | - |
| Incurrence of contingent liabilities | 13,743 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.